#ASCO24 #bcsm here we go!

Safely de-escalating axillary intervention, even in setting of cN+, is highly important for our pts' QoL, reducing their risk of lymphoedema. Look forward to future studies of head to head ax RT vs ax surg. #ASCO24 #bcsm #survivorship

Over a decade of effort to reduce adj RT from 5 wks to 3 to 1. Next step, select the pts who we can omit RT totally and confidently. #ASCO24 #bcsm #radiotherapy

Dr Charlotte Coles nicely elaborated the pragmatic approach of applying ultra-hypofractiobated RT to DCIS despite not having equivalent RCT evidence for the invasive counterpart. A decision that makes clinical and practical sense. #ASCO24 #bcsm

ER low as a separate entity compare with other ER+ tumours, RW database analysis shows that adjuvant ET is still important! #ERlow #ASCO24 #bcsm

More for ER-low BC, for #ASCO24 our group presents a real world analysis on ER exp and it's impact on CDK4/6i efficacy in ABC, and the ER low group performed really poorly! ER level expression is important when making tx decision. meetings.asco.org/abstracts-pres… #ASCO24 #bcsm #ERlow

Long awaited results of postMONARCH. Treatment beyond CDK46i progression with Abema yields modest PFS over fulv (mainly in the context of palbo as 1st line... and visceral met -ve). #ASCO24 #bcsm

Full house awaiting DB06 LBA at 730am! #ASCO24 #bcsm

When you have a full #ASCO24 room at 7 am, you know it will be a pretty relevant session. #DB06 G Curigliano MD PhD

DB06 showed consistent PFS benefit for the HER2-ultra low subgroup as that for HER2-low. Tdxd v chemo 13.2m v 8.3m. A landmark moment for the tx landscape of HR+ ABC!! #ASCO24 #bcsm

Giuseppe Curigliano (G Curigliano MD PhD) presents DB06. Among pts with endocrine-refractory HR+ HER2-low/ultralow MBC, 1L T-DXd significantly & meaningfully improved PFS over chemo (13.2 vs 8.1 mo, HR 0.62, p<0.001). 11% ILD (0.7% G5). New option in the 1L and validation of HER2-ultralow.

HER2-ultralow officially joins the pie chart of targetable HER2 expressions. Next step: unlocking the full spectrum with quantitative assays. #ASCO24 #DB06

#ESMO24 Natalee 4 yr update with increasing benefit in all subgroups c/w carryover effect. 36% <3 yrs; 20% due to AEs. 8.6% gr 3+ LFTs AEs. Nitrosamine issue 2b imminently resolved. Exciting advance for mod/hi risk ES HR+ BC. OncoAlert

Otto Metzger (Otto Metzger) presents the practice-changing results from the #PATINA phase 3 trial: adding palbociclib to maintenance ET after 1L THP for HR+/HER2+ MBC significantly and meaningfully improved PFS (44 vs 29 months, HR 0.74, p=0.007). 44 months!!!!!!!!!!!!!!!!!!!!!!!!

Press release: T-DXd + pertuzumab improved PFS vs THP in first-line HER2+ mBC. The T-DXd monotherapy arm remains blinded. The PFS advantage with T-DXd+P is likely to be considerable. Enough to convince breast med oncs to drop the taxane induction strategy? astrazeneca.com/media-centre/p…

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment. #ASCO25

Sung-Bae Kim presents a phase 3 trial of oral paclitaxel (DHP107) vs IV paclitaxel, mostly conducted in China/Korea. Similar PFS, OS and ORR between the oral and IV formulations. Less neuropathy, but more neutropenia with the oral taxol. We NEED an oral taxane in clinic! #ASCO25

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

Fantastic programme and great insights by global experts at the HKIOF2025! So lovely to see Paolo Tarantino in HK, inspirational and beaming with energy as always! #HKIOF #InternationalSelfieDay

The ADC MASTERCLASS at HKIOF by Paolo Tarantino #ADC #HKIOF25